Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

This year, urgent care centers nationwide are bracing for another intense respiratory season, with a notable rise in patient volumes expected. In 2022, there were over 206 million urgent care visits recorded, exceeding the 131 million emergency department visits. These centres have become the front line in managing respiratory illnesses.  At several of the recent […]

The post HealthTrackRx: Advancing Urgent Care Diagnostic Capabilities  appeared first on Medical News Bulletin.

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

IV therapies used to be limited to hospital settings where patients could be given medications, fluids, and even nutrients when they were sick. The usage of IVs was limited and kept within these environments. These IVs delivered timely treatments for cancer, offered hydration during sickness, and gave medications that could not be given orally. And […]

The post The Growing Use of IV Therapies for Medicine and Everyday Use appeared first on Medical News Bulletin.

The FDA has approved inebilizumab-cdon (Uplizna, Amgen) for adults with anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody positive generalized myasthenia gravis, according to a press release.
The approval came in the wake of the phase 3, double-blind, randomized, placebo-controlled MINT trial, published by Richard Nowak, MD, MS, director of the Myasthenia Gravis Clinic at Yale University, and colleagues, in the New England Journal of Medicine.
As Healio previously reported, the study included 238 patients with gMG, an autoimmune disease marked by muscle weakness,

SAN ANTONIO — A digital toolkit with patient scripts, risk calculator comparisons and more could help primary care and OB/GYN providers increase risk-informed breast cancer screening.
Reviewers of the toolkit said it had high usability, demonstrated clinical relevance, improved communication and could help with decision making, according to Amanda M. Woodworth, MD, FACS, FSSO, director of breast health at Keck Medicine of USC/Henry Mayo Newhall Hospital, who discussed the feedback at San Antonio Breast Cancer Symposium.
“Providers, please, give this a try,” Woodworth told Healio. “Not every

SAN ANTONIO — More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 did not undergo testing for BRCA mutations, according to a retrospective analysis.
Less than half underwent testing for three other potentially actionable mutations, findings presented at San Antonio Breast Cancer Symposium showed.
“Broader and more timely testing for breast cancer biomarkers is warranted to identify patients who are eligible for targeted therapies,” Siddhartha Yadav, MBBS, MD, medical oncologist at Mayo Clinic in Rochester, Minnesota, said during a presentation.

SAN ANTONIO — Menopausal hormone therapy did not elevate risk for breast cancer among women with inherited BRCA mutations, according to observational study results presented at San Antonio Breast Cancer Symposium.
Risk did not vary based on the type of hormone therapy formulation used, nor whether women had BRCA1 or BRCA2 mutations.
The findings demonstrate that clinicians should follow a personalized approach to help women with BRCA mutations manage chronic or acute effects of menopause — whether natural or induced by surgery — provided there are no contraindications, investigators concluded.

Click here to read the Cover Story, "Global ophthalmology: Learning through teaching."
Being a physician is a privilege because your skills can truly change a life.
Restoring sight gives someone back their independence, and using your gifts in volunteer service is one of the most meaningful, impactful ways to make a difference in our world.
My full-time job is leading Eye Corps, a nonprofit in Tanzania focused on curing blindness. We have restored vision to nearly 10,000 people, creating change through service, education, equipment and entrepreneurship.
But for the first 25 years of my career, I

SAN ANTONIO — “Is omission of the sentinel lymph node biopsy safe in early breast cancer in patients treated with breast conserving therapy and whole-breast radiotherapy?”
Bypassing sentinel lymph node biopsy in patients with clinically node-negative, hormone receptor-positive, HER2-negative early-stage breast cancer did not increase regional recurrence or survival after a median follow-up of 5 years, according to data from San Antonio Breast Cancer Symposium.
“Previous studies showed safety of less auxiliary treatment, and in early breast cancer, the sentinel lymph node biopsy was often

The FDA has approved berotralstat oral pellets for prophylactic use in patients aged 2 to less than 12 years with hereditary angioedema, according to a press release from BioCryst Pharmaceuticals.
“Until now, the only treatment options for patients under 12 years of age, whether long-term prophylaxis or on-demand therapy, were delivered intravenously or through subcutaneous injection,” Charlie Gayer, MBA, president and chief commercial officer of BioCryst, told Healio.
Berotralstat (Orladeyo; BioCryst Pharmaceuticals) has been approved as a prophylaxis for hereditary angioedema (HAE) attacks in

ORLANDO — In this video, Shazia K. Nakhoda, MD, discusses a study that showed time-limited triple combination therapy with pirtobrutinib yielded ‘favorable’ results in patients with chronic lymphocytic leukemia.
In the study presented at the ASH Annual Meeting and Exposition, patients with CLL received a combination of pirtobrutinib (Jaypirca, Eli Lilly & Co.) with obinutuzumab (Gazyva, Genentech) and venetoclax (Venclexta; AbbVie, Genentech). Results showed a high rate of undetectable minimal residual disease, particularly in the bone marrow.
“This is really